AKAP6

Across TCGA pan-cancer cohorts, AKAP6 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated AKAP6 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher AKAP6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AKAP6 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

THYM, UCEC, and KIRC are the cancer types where AKAP6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCEC	DFS	Median	II,III,IV	1.000	0.293	<.001	36	view →
KIRC	DFS	Median	IV	0.205	0.603	.001	28	view →
ACC	DFS	Median	All	0.046	0.753	<.001	24	view →
SARC	DFS	Median	All	0.146	0.517	.022	6	view →
PAAD	DFS	Median	All	0.006	0.505	<.001	6	view →
LUAD	DFS	Median	II,III,IV	0.899	0.664	.024	6	view →
COAD	OS	Median	III,IV	0.237	0.706	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

AKAP6–THYM (OS)

Open the THYM breakdown →